We would love to hear your thoughts about our site and services, please take our survey here.
My view on the valuation is failure to secure production orders in volume...yet and trust issues with management.
DHSC contract cancelled and not RNS'D
Avacta Affidx paused just after the fundraise. Some may view this as a bit too convenient.
Things to look forward to.
2.7 Million high margin LFT deal. Tech transfer guidance within 2 months. We are beyond this now so hopefully any day.
Vatic FDA EUA approval although this has gone remarkably quiet, no further communication from Abingdon or Vatic since tech transfer completion. Market clearly unnerved by this.
Taiwan - potential for a substantial revolving order subject to EUA (again). Initial RNS was pointless in my view without anticipated timescales.
A host of collaborations for tests - again no timescales offered.
Simplytest will hopefully gain traction.
Potentially very exciting times ahead but beyond frustrating currently. Funding isn't an issue short term. They need to get something over the line for this to take off and quickly.
Who knows what’s happening. Abingdon haven’t Tweeted anything since July 7th. Nothing from Vatic since May. Absolutely no positive sentiment here at the moment but it could change wit a single news item. Just wish they would hurry up before we’re worth nothing. Abingdon have created a nightmare for their original investor base.
To be fair to them, they’re good at Technical transfer. Approvals for their customers seems to be the stumbling block. Everything takes around a hundred years longer than expected. Disappointed with Vatic silence. Don’t think they should have bothered with the Taiwan RNS until approved. The Tech transfer for the 2.7 million deal is due now. Let’s hope they at least get this done in a timely fashion.
I’ve been watching some absolute dog stocks go ballistic this week, some on nothing but thin air and no income for the foreseeable. I’m really struggling to understand the lack of interest here with the pipeline of projects. It’s like the market is having none of it.
Yes of course. Everything’s spot on hence the sub 10p valuation. I’m not a doom monger and have a rather large holding here. Your last post about (it must be manipulation) sums it up really. It’s ok to talk about the good and bad. Something clearly is either being missed by the market or does not stack up.
6.3 million less 1.5 million subject to the court case outcome. It came to light yesterday that consortium members are outstanding payments from Abingdon and I there was quite a substantial VAT reversal which will now need to be paid. Happy to be corrected.
Makes you realise how little the market knows about AVCT. In HD2U’s defence, if your knowledge of AVCT is via Abingdon’s communications then he’s not wrong on the LFT front. Obviously AVCT have a great deal more going on.
Agree. The RNS is a bit disingenuous. The management really don’t fill me with confidence.
The monies received from DHSC, once received, will provide additional working capital and be deployed to help fund the Company's various growth initiatives underway.